Growth Factors & Signaling

Ipamorelin

For Research Use Only. Not for Human or Veterinary Use.

Overview

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that selectively activates the ghrelin receptor (GHSR-1a). Its defining feature in the research literature is selectivity: it stimulates growth-hormone release with little effect on prolactin, cortisol or ACTH, and with minimal appetite stimulation — which distinguishes it from earlier GHRPs. It is a research compound.

Chemical Profile

PropertyValue
CAS number170851-70-4
ClassPentapeptide GHSR-1a agonist
Amino-acid sequenceH-Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular formulaC₃₈H₄₉N₉O₅
Molecular weight711.86 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Ipamorelin at a glance
Class
Pentapeptide GHSR-1a agonist
Research status
Preclinical and limited clinical
Study route
Subcutaneous
Half-life
≈ 2 h
Key feature
Selective GH release, minimal prolactin/cortisol

Mechanism of Action

Ipamorelin binds GHSR-1a like the other GHRPs, but its selectivity profile is the point of interest: it drives GH release without meaningfully raising prolactin, cortisol or ACTH, and with little of ghrelin’s appetite effect. That “cleaner” signal is why it is often used as the reference selective secretagogue.

ComponentDetail
Primary targetGHSR-1a (ghrelin receptor)
G-protein couplingGαq/11 → PLC → IP₃/DAG → Ca²⁺
GH releasePotent
ProlactinMinimal
Cortisol / ACTHNo significant elevation
AppetiteMinimal (distinguishes it from ghrelin)

Pharmacology

ParameterValue
Half-life (t½)≈ 2 h
Bioavailability (SC)≈ 80–90%
Time to peak (Tmax)≈ 15–30 min
MetabolismProteolytic degradation
Route of administrationSubcutaneous
EliminationRenal (peptide fragments)

Research Evidence

Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
Rat pituitary cellsPotent, selective GH releaseRaun K, et al. (1998/2005)
Ovariectomized ratsBone-formation markersGH-secretagogue bone literature
Healthy-volunteer studyGH response and selectivityIpamorelin clinical literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Potent, selective GH release with minimal prolactin/cortisolpituitary modelsRaun K et al.
Bone-formation markers in ovariectomized modelsrat boneGH-secretagogue literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 200–500 µg per injection, in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~2–4 weeks
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions
Hormonal crosstalkMinimal prolactin/cortisol elevation (its selling point)
AppetiteMinimal
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble
logP≈ −1.5 (hydrophilic)
pH (reconstituted)5.0–6.5
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

Ipamorelin is a C-terminally amidated pentapeptide made by Fmoc solid-phase synthesis. The non-standard residues — Aib and D-2-naphthylalanine — plus the two D-amino acids are what require dedicated building blocks.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide resin (C-terminal amide)
Special residuesAib, D-2-Nal, D-Phe
CouplingHBTU / HOBt with DIPEA
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Confirm the D-residues and the α-aminoisobutyric acid (Aib).

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 712 Da
MALDI-TOFMass confirmation[M+H]⁺ ≈ 712 Da
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 712 Da). Confirm the D-residues and the α-aminoisobutyric acid (Aib).

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Confirm the D-residues and the α-aminoisobutyric acid (Aib).

Selected References

  • Raun K, et al. Ipamorelin, the first selective growth-hormone secretagogue. European Journal of Endocrinology.
  • Growth-hormone-secretagogue and GHSR-1a pharmacology reviews.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Ipamorelin — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote